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• Data from a multi-state hospital system included all
tPA-treated patients discharged between January 2011 
and May 2018. 
• Patients who were <18 years old, received 
thrombectomy, transferred to another hospital, or had 
an inpatient stroke were excluded. 
• Outcomes included percentage of patients who 
experienced any complication, sICH, life-threatening 
systemic hemorrhage, other serious complication, or in-
hospital mortality or discharge to hospice. 
• Chi-squared and Fisher’s exact tests and generalized 
linear models were used to compare outcomes 
between patients with MIS (NIHSS≤5) and moderate-
to-severe strokes (NIHSS>5).
• Risk of complication versus potential benefit is 
considered when deciding whether to treat acute 
ischemic stroke with IV alteplase (tPA).  
• Symptomatic intracerebral hemorrhage (sICH) rate is 
often quoted as 6.4% based on the NINDS trials.  
• sICH risk often makes patients and physicians wary of 
tPA treatment for mild ischemic stroke (MIS)1.
• 2018 ASA guidelines removed MIS as a relative 
contraindication to tPA2.
• A few small studies have revealed mixed outcomes and 
treatment complications in MIS2,3. 
• This study compared tPA-related complications in MIS 
vs. moderate-to-severe stroke in a large hospital system.
• Complications from tPA, including sICH and in-hospital mortality or discharge to 
hospice, were less frequent than in the NINDS studies.
• Complications from tPA in MIS were less frequent than moderate-to-severe stroke.
• Our data suggests that tPA treatment poses minimal risk in MIS.
• A total of 3,087 patients met inclusion criteria, of these 36.0% (1,111) had a mild stroke.
• MIS patients were less likely than moderate-to-severe stroke patients to have sICH (1.3% vs. 4.4%; p<0.001), life-
threatening systemic hemorrhage (0% vs. 0.8%; p<0.001), or other serious complications (0.5% vs. 2.1%; 
p<0.001) (Figure 1). 
• In multivariate analysis, patients with MIS were 73% (95% CI: 56, 83; p<0.001) less likely than those with 
moderate-to-severe stroke to have any complication and 87% (95% CI: 79, 92; p<0.001) less likely to die or 
discharge to hospice after adjusting for age, sex, hospital, and history of atrial fibrillation, hypertension, diabetes, 
and coronary artery disease or prior myocardial infarction (Figure 2).
NIHSS≤5
(n=1,111)
NIHSS>5
(n=1,976)
P-
value
Age, mean (SD) 65.53 (14.52) 73.02 (15.08) <0.001
Admit NIHSS, 
median [IQR]
3.00 
[2.00, 4.00]
12.00
[8.00, 19.00]
<0.001
Female, % (n) 45.0 (500) 52.1 (1,029) <0.001
Stroke Certification 
Level, % (n)
<0.001
Comprehensive 14.3 (159) 8.1 (160)
None 4.7 (52) 5.2 (103)
Primary 81.0 (900) 86.7 (1,713)
Arrived via EMS, % 
(n)
61.7 (685) 86.9 (1,718) <0.001
History of Atrial 
Fibrillation, % (n)
11.5 (130) 25.3 (517) <0.001
History of 
Hypertension, % (n)
66.2 (745) 74.2 (1,490) <0.001
History of Diabetes, 
% (n)
25.0 (282) 28.6 (573) 0.038
History of Coronary 
Artery Disease or 
Prior MI, % (n)
19.9 (224) 24.9 (500) 0.002
Smoker, % (n) 16.9 (190) 16.7 (335) 0.935
Figure 1:Univariate Analyses for Outcomes of MIS Versus Moderate-to-Severe Stroke Patients. Table 1. Patient Characteristics1
Figure 2: Multivariate Analyses for Outcomes of MIS 
Versus Moderate-to-Severe Stroke Patients. 
1. Mutlivariate analyses adjusted for variables listed above.
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